Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$9.73-7.95%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CRVS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund operations into Q2 2028 | Corvus plans to fund operations into Q2 2028. | Improving | fails to maintain funding through Q2 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The thesis is on watch: management is advancing soquelitinib trials and has funding guidance into the second quarter of 2028, but recent financial performance is weak and confidence in the evidence is low.
The snapshot gives no valuation or market-expectations evidence, so whether the shares look cheap or expensive and what the market already assumes cannot be assessed. The financing supports operations, but it does not remove the risk that ongoing losses and trial uncertainty weigh on the thesis.
Near term, losses and cash burn remain elevated as clinical work expands, despite management being on track with its funding-runway priority. The August earnings miss and a high-miss-rate industry make the next report a risk to watch; the evidence does not establish a clear path to improved financial performance. Over the multi-year view, progress depends on clinical development, including Phase 3 PTCL and Phase 2 atopic dermatitis trials.
A guidance cut on the next call would be a negative signal, while continued delivery on trial plans and the stated funding runway would support the thesis. A weakening jobs trend could add pressure to sector sentiment, while strong results and guidance from healthcare bellwethers could provide a sector tailwind. The snapshot does not show clinical trial outcomes, so their progress and eventual results remain key uncertainties.
Over the next one to three years, CRVS is a watch-state, high-risk thesis centered on clinical progress and adequate funding, with rising losses and limited evidence on valuation or trial outcomes. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Corvus Pharmaceuticals, Inc.'s published investment case. The stated target is operating loss does not exceed $14.88M. |
| Under Pressure |
| operating loss rises above $14.88M |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Market expectations for product success | A supporting condition in Corvus Pharmaceuticals, Inc.'s published investment case. The stated target is market expectations align with actual product success. | Improving | market expectations exceed actual product success | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.95 → $-0.94 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.95 | $5,682,000 | 3 / 4 |
| 2026-07-25 | $-0.95 | $5,682,000 | 3 / 4 |
| 2026-07-26 | $-0.85 | $4,545,600 | 4 / 3 |
| 2026-07-27 | $-0.95 | $5,682,000 | 3 / 4 |
| 2026-07-28 | $-0.95 | $5,682,000 | 3 / 4 |
| 2026-07-29 | $-0.85 | $4,545,600 | 4 / 3 |
| 2026-07-30 | $-0.95 | $5,682,000 | 3 / 4 |
| 2026-07-31 | $-0.96 | $4,545,600 | 4 / 5 |
| 2026-08-01 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-02 | $-0.96 | $4,545,600 | 4 / 5 |
| 2026-08-03 | $-0.96 | $4,545,600 | 4 / 5 |
| 2026-08-04 | $-0.96 | $4,545,600 | 4 / 5 |
| 2026-08-05 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-06 | $-0.96 | $4,545,600 | 4 / 5 |
| 2026-08-07 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-08 | $-0.96 | $4,545,600 | 4 / 5 |
| 2026-08-09 | $-1.07 | $4,545,600 | 4 / 5 |
| 2026-08-10 | $-1.07 | $4,545,600 | 4 / 5 |
| 2026-08-11 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-12 | $-1.07 | $4,545,600 | 4 / 5 |
| 2026-08-13 | $-1.07 | $4,545,600 | 4 / 5 |
| 2026-08-14 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-15 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-16 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-17 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-18 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-19 | $-0.87 | $3,788,000 | 5 / 3 |
| 2026-08-20 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-21 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-22 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-23 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-24 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-25 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-26 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-27 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-28 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-29 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-30 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-08-31 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-01 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-02 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-03 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-04 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-05 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-06 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-07 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-08 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-09 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-10 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-11 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-12 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-13 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-14 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-15 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-16 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-17 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-18 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-19 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-20 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-21 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-22 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-23 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-24 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-25 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-26 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-27 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-28 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-29 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-09-30 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-01 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-02 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-03 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-04 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-05 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-06 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-07 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-08 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-09 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-10 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-11 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-12 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-13 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-14 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-15 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-16 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-17 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-18 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-19 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-20 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-21 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-22 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-23 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-24 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-25 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-26 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-27 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-28 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-29 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-30 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-10-31 | $-0.93 | $3,788,000 | 5 / 3 |
| 2026-11-01 | $-0.94 | $4,545,600 | 5 / 3 |
| 2026-11-02 | $-0.94 | $4,545,600 | 5 / 3 |
| 2026-11-03 | $-0.94 | $4,545,600 | 5 / 3 |
| 2026-11-04 | $-0.94 | $4,545,600 | 5 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.